Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms

Pinkerton, JoAnn V.; Constantine, Ginger D.; Hwang, Eunhee; Cheng, Ru-fong J.

doi:10.1097/gme.0b013e31826421a8

Cited by 41 publications

(25 citation statements)

References 29 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several non-hormonal compounds including clonidine, gabapentin, and some of serotonin and serotonin-norepinephrine reuptake inhibitors have been used for relief of VMS. Desvenlafaxine, a novel serotonin norepinephrine reuptake inhibitor, has been shown to be effective for the treatment of moderate to severe hot flashes associated with menopause [11,12,13,14,15,16,17,18]; however, the results have not been entirely consistent [19]. There have been potential cardiovascular risks associated with the use of desvenlafaxine in this patient population [11].…”

Section: Introductionmentioning

confidence: 82%

“…After reviewing the full texts, two studies [11,24] reported the same results and we only chose the trial of Wyrwich et al [11] in the meta-analysis, thus only six studies [11,12,13,17,19,25] met the inclusion criteria. Characteristics of the six RCTs are listed in table 1.…”

Section: Resultsmentioning

confidence: 99%

“…Six trials [12,13,17,18,19,25 ]describing administration of desvenlafaxine 100 mg to patients included data on adverse events. The adverse effects included nausea, constipation, diarrhea, dry mouth, hypertension, somnolence, asthenia dizziness, insomnia, etc.…”

Section: Resultsmentioning

confidence: 99%

“…All the included studies [11,12,13,17,19,25] evaluated the change of moderate and severe hot flashes frequency per day. As shown in figure 2, 609 were assigned to the desvenlafaxine 100 mg groups (12 weeks), 558 were assigned to the desvenlafaxine 150 mg groups (12 weeks), and 399 were assigned to the desvenlafaxine 100 mg groups (≥26 weeks).…”

Section: Resultsmentioning

confidence: 99%

“…Characteristics of the six RCTs are listed in table 1. Six trials [11,12,13,17,19,25] were composed of 1,931 postmenopausal women, including 1,195 who had received desvenlafaxine and 736 who had received placebo. The change of moderate and severe hot flashes frequency efficacy analysis was carried out on the modified intention-to-treat (ITT) population in all included trials.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and Safety of Desvenlafaxine Treatment for Hot Flashes Associated with Menopause: A Meta-Analysis of Randomized Controlled Trials

Sun

Yanqing

Zhang³

2013

Gynecol Obstet Invest

View full text Add to dashboard Cite

Vasomotor symptoms, such as daytime hot flashes and nighttime awakenings due to hot flashes, are commonly associated with menopausal women. The aim of this study was to assess desvenlafaxine in moderate to severe hot flashes in postmenopausal women. Electronic databases were searched for relevant randomized controlled trials that compared desvenlafaxine to placebo for postmenopausal women affected with hot flashes. The main outcomes were mean differences (MD) or standardized mean differences (SMD) and 95% confidence interval (CI) for change of the hot flashes. Six randomized controlled trials were identified in the meta-analysis. Pooled change of moderate and severe hot flashes frequency reduced SMD of -0.49 (95% CI -0.91 to -0.07) in desvenlafaxine 100 mg and -0.36 (95% CI -0.54 to -0.19) in desvenlafaxine 150 mg at week 12. Desvenlafaxine 100 mg reduced moderate and severe hot flashes frequency SMD of -0.74 (95% CI -1.05 to -0.44) within 26 weeks. There is no evidence for an increased risk of cardiovascular, cerebrovascular, or hepatic events associated with desvenlafaxine 100 mg/day. The meta-analysis suggests that treatment with desvenlafaxine 100 mg/day is associated with a significant reduction of moderate to severe hot flashes in postmenopausal women. Desvenlafaxine appears both safe and effective for treating hot flushes for up to 12 months.

show abstract